Feb. 18, 2022: National Advocacy Update- AMA
The AMA asked the Biden administration to take additional steps to remove the prescription status of naloxone—the overdose-reversing drug—to make it more available over the counter.
“As the overdose epidemic has worsened, given the FDA’s clear guidance there is no moral, medical, or safety-related reason for these life-saving overdose reversal agents to remain locked under prescription regulations,” the AMA wrote (PDF) the Office of National Drug Control Policy (ONDCP).
If not for naloxone, tens of thousands of additional Americans likely would have died from overdoses. The AMA greatly appreciates ONDCP has made increasing access to naloxone a high priority and recommended steps that would make it more widely available to harm-reduction organizations and individuals regardless of their insurance status. The letter notes that naloxone manufacturers are dragging their feet on making it more available over the counter.
TO CONTINUE: https://www.ama-assn.org/health-care-advocacy/advocacy-update/feb-18-2022-national-advocacy-update?utm_source=SFMC&utm_medium=email&utm_term=2182022&utm_content=22-9997_Advocacy_Update_021822&utm_campaign=Advocacy_Email_Newsletter_AdvocacyUpdate&utm_uid=15829237&utm_effort=#ama-urges-administration-to-save-lives-by-moving-naloxone-from-behind-the-counter